AMENDMENT to the Confirmation of OTC Warrant Transaction

Exhibit 10.7

AMENDMENT

dated as of September 9, 2008

to the

Confirmation of OTC Warrant Transaction

dated as of March 1, 2007

between

Mylan, Inc. (formerly Mylan Laboratories Inc.),
as seller,

Merrill Lynch International,
as buyer,

and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as agent

(the “Agreement”)

The parties have previously entered into the Agreement and have now agreed to amend the Agreement by the terms of this Amendment (this “Amendment”).

Accordingly, in consideration of the mutual agreements contained in this Amendment, the parties agree as follows:

1. Amendment of the Agreement

The Agreement is hereby amended by replacing the first paragraph opposite the caption “Limitations on Net Physical Settlement by Counterparty” with the following text:

“Notwithstanding anything herein or in the Agreement to the contrary, the number of Shares that may be delivered at settlement by Counterparty shall not exceed the product of 1.5 times the initial Number of Warrants at any time (“ Maximum Deliverable Share Amount ”), as adjusted by the Calculation Agent to account for any subdivision, stock-split, reclassification or similar dilutive event with respect to the Shares.”

2. Representations

Each party represents to the other party in respect of the Agreement, as amended pursuant to this Amendment, that all representa